Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.54 |
| ▸ | F13A1 | P00488 | 2/20 | 0.54 |
| ▸ | TGM1 | P22735 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 5/20 | 0.50 |
| ▸ | FAAH | O00519 | 3/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17534920 | 0.89 | TGM2 (0.67) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL10933862 | 0.81 | TGM2 (0.60) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL5580375 | 0.80 | MGLL (0.60) | MGLLFAAHHSP90AA1DDAH1PKM | |
| SCHEMBL439369 | 0.80 | TGM2 (0.79) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL8050517 | 0.80 | MMP1 (0.59) | LMNATHRB | |
| SCHEMBL19957406 | 0.80 | MGLL (0.46) | LMNAMGLLFAAHHSP90AA1DDAH1 | |
| SCHEMBL8194022 | 0.79 | HSP90AA1 (0.59) | MGLLFAAHHSP90AA1DDAH1PKM | |
| SCHEMBL12505801 | 0.77 | MGLL (0.56) | LMNAMGLLFAAHHSP90AA1DDAH1 | |
| SCHEMBL8505932 | 0.77 | SCN2A (0.63) | MGLLFAAHHSP90AA1DDAH1PKM | |
| SCHEMBL19911212 | 0.76 | NSD2 (0.59) | TGM2F13A1TGM1LMNATGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289504-B2 | Single protein nanocapsules for protein delivery with long-term effect | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289504-B2 | Single protein nanocapsules for protein delivery with long-term effect | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289504-B2 | Single protein nanocapsules for protein delivery with long-term effect | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-22 | — | — | US | disclosed |
| US-20110318297-A1 | SINGLE PROTEIN NANOCAPSULES FOR PROTEIN DELIVERY WITH LONG-TERM EFFECT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110318297-A1 | SINGLE PROTEIN NANOCAPSULES FOR PROTEIN DELIVERY WITH LONG-TERM EFFECT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110318297-A1 | SINGLE PROTEIN NANOCAPSULES FOR PROTEIN DELIVERY WITH LONG-TERM EFFECT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010104865-A2 | SINGLE PROTEIN NANOCAPSULES FOR PROTEIN DELIVERY WITH LONG-TERM EFFECT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318297-A1 | SINGLE PROTEIN NANOCAPSULES FOR PROTEIN DELIVERY WITH LONG-TERM EFFECT | CD2BP2, HSPBP1, HSPA2 | TGM2 1332/4885F13A1 1647/4885TGM1 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.